{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:06:49Z","timestamp":1792843609249,"version":"4.5.0"},"reference-count":29,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Thyroid\u00ae"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Anaplastic thyroid carcinoma (ATC) remains one of the most challenging malignancies to treat in the modern era. Most patients present with or develop recurrent\/metastatic incurable disease with poor response rates to conventional chemotherapy, and life expectancy is short. Next-generation sequencing (NGS) can be leveraged in ATC to identify oncogenic alterations that can be targeted with molecularly specific therapy, offering new effective treatment options to a subset of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient Findings:<\/jats:title>\n                    <jats:p>\n                      A 73-year-old man presenting with locally advanced papillary thyroid carcinoma containing a minor component of ATC was treated with surgery and iodine-131. He developed biopsy-confirmed ATC distant metastases that progressed on cytotoxic chemotherapy. NGS revealed several alterations, including a\n                      <jats:italic toggle=\"yes\">CCDC6-RET<\/jats:italic>\n                      gene fusion. The patient enrolled in LIBRETTO-001, a phase I\/II trial of the potent and specific RET inhibitor, LOXO-292. The patient tolerated LOXO-292 well and experienced a deep and durable partial response, ongoing beyond 19 months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      This clinically significant response achieved with LOXO-292 in a patient with a\n                      <jats:italic toggle=\"yes\">CCDC6-RET<\/jats:italic>\n                      fusion-positive ATC who had exhausted conventional treatment options highlights the importance of conducting tumor genomic profiling in patients with ATC to identify uncommon but actionable genomic alterations, such as\n                      <jats:italic toggle=\"yes\">RET<\/jats:italic>\n                      gene fusions.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/thy.2019.0477","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T06:55:33Z","timestamp":1586933733000},"page":"1384-1389","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":44,"title":["Response to RET-Specific Therapy in\n                    <i>RET<\/i>\n                    Fusion-Positive Anaplastic Thyroid Carcinoma"],"prefix":"10.1177","volume":"30","author":[{"given":"Dora","family":"Dias-Santagata","sequence":"first","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen K.","family":"Lennerz","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Sadow","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan P.","family":"Frazier","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandya","family":"Govinda Raju","sequence":"additional","affiliation":[{"name":"Loxo Oncology, Inc., Stamford, Connecticut, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dahlia","family":"Henry","sequence":"additional","affiliation":[{"name":"Loxo Oncology, Inc., Stamford, Connecticut, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trisha","family":"Chung","sequence":"additional","affiliation":[{"name":"Loxo Oncology, Inc., Stamford, Connecticut, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Kherani","sequence":"additional","affiliation":[{"name":"Loxo Oncology, Inc., Stamford, Connecticut, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Michael","family":"Rothenberg","sequence":"additional","affiliation":[{"name":"Loxo Oncology, Inc., Stamford, Connecticut, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori J.","family":"Wirth","sequence":"additional","affiliation":[{"name":"Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,4,15]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"2018 SEER Cancer Stat Facts: Thyroid Cancer. Bethesda MD: National Cancer Institute."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.wjorl.2018.05.006"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2012.0302"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-3545-5"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85271"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddu749"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0373"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.6785"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1005467"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.09.050"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0273"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/emmm.201000070"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1679"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0279"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7574"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0387"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714448"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1101\/mcs.a001115"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.139"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0636"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.175"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy137"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.102"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.08.304"},{"key":"e_1_3_3_27_2","unstructured":"Wirth L Cabanillas M Sherman E Solomon B LeBoulleux S Robinson B Taylor M Bauer T Patel J Reckamp K Lorch J Tan D Boni V Smith S Tuch B Ebata K Zhu E Nguyen M Huang X Cruickshank S Rothenberg S Oxnard G Besse B Schlumberger M Drilon A Subbiah V Shah M. 2018. Clinical activity of LOXO-292 a highly selective RET inhibitor in patients with RET-altered thyroid cancers: an update from ASCO 2018. In: 88th Annual Meeting of the American Thyroid Association Oct 3\u20137 2018."},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22229"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2013.11.007"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-019-03114-1"}],"container-title":["Thyroid\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/thy.2019.0477","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/thy.2019.0477","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/thy.2019.0477","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T10:12:31Z","timestamp":1782382351000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/thy.2019.0477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,15]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1089\/thy.2019.0477"],"URL":"https:\/\/doi.org\/10.1089\/thy.2019.0477","relation":{},"ISSN":["1050-7256","1557-9077"],"issn-type":[{"value":"1050-7256","type":"print"},{"value":"1557-9077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,15]]}}}